This fist clinical trial (NCT02944162) included only 3 patients with relapsed or refractory AML and used anti-CD33 CAR-NK cells as therapeutic agent, generated by transduction of NK-92-MI cells with the CD33-CD28-4-1BB-CD3ζ CAR construct. Here, CD28 is linked to acute myeloid leukemia.